BR0017437A - Composições farmacêuticas contendo polipéptido líquidas estabilizadas - Google Patents

Composições farmacêuticas contendo polipéptido líquidas estabilizadas

Info

Publication number: BR0017437A
Authority: BR; Brazil
Prior art keywords: acid; polypeptide; amino acid; arginine; variants
Prior art date: 1999-10-04

Application number

BR0017437A

Other languages

English (en)

Other versions

BRPI0017437B1 (pt

BRPI0017437B8 (pt

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-04

Filing date

2000-10-03

Publication date

2002-09-17

2000-10-03 Application filed by Chiron Corp filed Critical Chiron Corp

2002-09-17 Publication of BR0017437A publication Critical patent/BR0017437A/pt

2016-06-07 Publication of BRPI0017437B1 publication Critical patent/BRPI0017437B1/pt

2021-05-25 Publication of BRPI0017437B8 publication Critical patent/BRPI0017437B8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Virology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Hematology (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)

BRPI0017437A 1999-10-04 2000-10-03 composição farmacêutica estabilizada contendo polipeptídeo il-2, método para aumentar estabilidade de interleucina-2 em uma composição farmacêutica, e uma forma seca da composição BRPI0017437B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15769699P	1999-10-04	1999-10-04
PCT/US2000/027156 WO2001024814A1 (en)	1999-10-04	2000-10-03	Stabilized liquid polypeptide-containing pharmaceutical compositions
BR0014486-0A BR0014486A (pt)	1999-10-04	2000-10-03	Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado

Publications (3)

Publication Number	Publication Date
BR0017437A true BR0017437A (pt)	2002-09-17
BRPI0017437B1 BRPI0017437B1 (pt)	2016-06-07
BRPI0017437B8 BRPI0017437B8 (pt)	2021-05-25

Family

ID=22564882

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BR0014486-0A BR0014486A (pt)	1999-10-04	2000-10-03	Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
BRPI0017437A BRPI0017437B8 (pt)	1999-10-04	2000-10-03	composição farmacêutica estabilizada contendo polipeptídeo il-2, método para aumentar estabilidade de interleucina-2 em uma composição farmacêutica, e uma forma seca da composição

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BR0014486-0A BR0014486A (pt)	1999-10-04	2000-10-03	Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado

Country Status (18)

Country	Link
US (4)	US6525102B1 (pt)
EP (2)	EP1220682B1 (pt)
JP (2)	JP2003510368A (pt)
CN (2)	CN1245216C (pt)
AT (2)	ATE345810T1 (pt)
AU (2)	AU783306B2 (pt)
BR (2)	BR0014486A (pt)
CA (2)	CA2386228A1 (pt)
CZ (2)	CZ305123B6 (pt)
DE (2)	DE60031999T2 (pt)
ES (1)	ES2276698T3 (pt)
HU (3)	HU227347B1 (pt)
IL (3)	IL149008A0 (pt)
NO (2)	NO20021567L (pt)
NZ (2)	NZ529856A (pt)
PL (2)	PL354987A1 (pt)
PT (1)	PT1491208E (pt)
WO (1)	WO2001024814A1 (pt)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7006874B2 (en) *	1996-01-05	2006-02-28	Thermage, Inc.	Treatment apparatus with electromagnetic energy delivery device and non-volatile memory
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
CN1245216C (zh) *	1999-10-04	2006-03-15	希龙公司	稳定化的含多肽的液体药物组合物
EP1244432A2 (en) *	1999-12-30	2002-10-02	Chiron Corporation	Methods for pulmonary delivery of interleukin-2
US6495534B2 (en)	2000-05-15	2002-12-17	Pharmacia & Upjohn Spa	Stabilized aqueous suspensions for parenteral use
EP1935431A3 (en)	2000-05-15	2008-08-13	Health Research, Inc.	Cancer treatments by using a combination of an antibody against her2 and interleukin-2
JP4147234B2 (ja) *	2004-09-27	2008-09-10	キヤノン株式会社	吐出用液体、吐出方法、カートリッジ及び吐出装置
US8703126B2 (en)	2000-10-12	2014-04-22	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
JP4340062B2 (ja)	2000-10-12	2009-10-07	ジェネンテック・インコーポレーテッド	粘度の減少した濃縮タンパク質製剤
WO2002076445A1 (fr) *	2001-03-23	2002-10-03	Ajinomoto Co., Inc.	Agents utilises pour lutter contre les maladies provoquees par le stress et medicaments associes
US6887462B2 (en) *	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
DE10149030A1 (de) *	2001-10-05	2003-04-10	Viscum Ag	Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
IL161407A0 (en)	2001-10-15	2004-09-27	Chiron Corp	Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
EP1450847B1 (en)	2001-11-13	2010-09-29	Genentech, Inc.	APO2 ligand/ TRAIL formulations and uses thereof
EP1946776B1 (en) *	2002-02-27	2017-01-18	Immunex Corporation	Stabilized tnfr-fc composition comprising arginine
SI1478394T1 (sl) *	2002-02-27	2008-12-31	Immunex Corp	STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US6964778B1 (en) *	2002-09-06	2005-11-15	Health Research, Inc.	Temperature controlled content release from liposomes
US6991805B1 (en) *	2002-09-06	2006-01-31	Health Research, Inc.	Temperature sensitive control of liposome-cell adhesion
JP5057648B2 (ja) *	2002-09-26	2012-10-24	塩野義製薬株式会社	安定化されたタンパク組成物
DK1599222T3 (da) *	2003-01-08	2009-04-27	Novartis Vaccines & Diagnostic	Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
EP1803445A3 (en) *	2003-01-08	2007-11-21	Novartis Vaccines and Diagnostics, Inc.	Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
EP1589949B1 (en) *	2003-01-08	2008-08-13	Novartis Vaccines and Diagnostics, Inc.	Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
US20040208870A1 (en) *	2003-01-30	2004-10-21	Medimmune, Inc.	Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
US20040208869A1 (en) *	2003-01-30	2004-10-21	Medimmune, Inc.	Uses of anti-integrin alphanubeta3 antibody formulations
BRPI0408925A (pt) *	2003-03-31	2006-04-04	Alza Corp	veìculos de fase simples não-aquosos e formulações utilizando tais veìculos
AU2004229335C1 (en)	2003-04-04	2010-06-17	Genentech, Inc.	High concentration antibody and protein formulations
US7445933B2 (en) *	2003-07-16	2008-11-04	Abbott Laboratories, Inc.	Stable calibrators or controls for measuring human natriuretic peptides
US7291501B2 (en) *	2003-07-16	2007-11-06	Abbott Laboratories	Stable compositions for measuring human natriuretic peptides
US7851433B2 (en) *	2003-08-13	2010-12-14	Novartis Vaccines And Diagnostics, Inc.	Method of purifying TFPI and TFPI analogs
US7141544B2 (en)	2003-10-10	2006-11-28	Baxter International, Inc.	Stabilization of pharmaceutical protein formulations with small peptides
DE10348550A1 (de) *	2003-10-20	2005-06-16	Hexal Biotech Forschungsgmbh	Stabile wässrige G-CSF-haltige Zusammensetzungen
JP4746552B2 (ja)	2003-11-04	2011-08-10	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
US20050136542A1 (en) *	2003-12-19	2005-06-23	Beckman Coulter, Inc.	Stabilized liquid reference solutions
US8338374B2 (en) *	2003-12-23	2012-12-25	Pharmacia Corporation	Stable growth hormone liquid formulation
EP1712240B1 (en) *	2003-12-25	2015-09-09	Kyowa Hakko Kirin Co., Ltd.	Stable water-based medicinal preparation containing antibody
EP1703895A2 (en) *	2004-01-13	2006-09-27	Vasogenix Pharmaceuticals, Inc.	Controlled release cgrp delivery composition for cardiovascular and renal indications
CA2552758A1 (en) *	2004-01-13	2005-08-04	Vasogenix Pharmaceuticals, Inc.	Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
WO2005070444A2 (en) *	2004-01-13	2005-08-04	Vasogenix Pharmaceuticals, Inc.	Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
AU2005319099B2 (en) *	2004-02-02	2010-09-16	Ambrx, Inc.	Modified human growth hormone
WO2005110059A2 (en) *	2004-03-17	2005-11-24	Chiron Corporation	Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
JP2007531738A (ja)	2004-04-02	2007-11-08	アムジエン・インコーポレーテツド	ＩＬ−１ｒａの凝集を低下させる方法
EA010979B1 (ru) *	2004-06-01	2008-12-30	Арес Трейдинг С.А.	Стабилизированные жидкие препаративные формы интерферона
US20060051347A1 (en)	2004-09-09	2006-03-09	Winter Charles M	Process for concentration of antibodies and therapeutic products thereof
DE102004059776A1 (de) *	2004-09-17	2006-04-06	Deutsches Zentrum für Luft- und Raumfahrt e.V.	Brennstoffzellensystem
JP4147235B2 (ja) *	2004-09-27	2008-09-10	キヤノン株式会社	吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
US20060188555A1 (en) *	2005-01-21	2006-08-24	Micheal Cormier	Therapeutic peptide formulations with improved stability
CN100337684C (zh) *	2005-05-11	2007-09-19	北京双鹭药业股份有限公司	一种胸腺五肽的水溶液制剂、其制备方法及应用
CN100342909C (zh) *	2005-05-11	2007-10-17	北京双鹭药业股份有限公司	一种胸腺素α1的水溶液制剂、其制备方法及应用
CN100336557C (zh) *	2005-05-11	2007-09-12	北京双鹭药业股份有限公司	一种生长抑素的水溶液制剂、其制备方法及应用
US7964200B2 (en)	2005-05-18	2011-06-21	Children's Hospital & Research Center At Oakland	Methods and compositions for immunizing against Chlamydia infection
KR100769709B1 (ko) *	2005-05-31	2007-10-23	주식회사 대웅	인성장호르몬을 함유하는 안정한 액상 제제
WO2006138181A2 (en)	2005-06-14	2006-12-28	Amgen Inc.	Self-buffering protein formulations
US20070027105A1 (en)	2005-07-26	2007-02-01	Alza Corporation	Peroxide removal from drug delivery vehicle
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
US20070191271A1 (en) *	2006-02-10	2007-08-16	Dow Pharmaceutical Sciences	Method for stabilizing polypeptides lacking methionine
WO2007103425A2 (en) *	2006-03-06	2007-09-13	Novartis Ag	Kits and methods for preparing pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi)
TW200806317A (en) *	2006-03-20	2008-02-01	Wyeth Corp	Methods for reducing protein aggregation
GEP20125628B (en) *	2006-04-21	2012-09-10	Novartis Ag	Pharmaceutical compositions containing antagonist anti-cd40 antibody
PT2049148T (pt) *	2006-07-06	2016-12-30	Daewoong Co Ltd	Formulação líquida estável da hormona do crescimento humana
CN105363022A (zh) *	2006-07-06	2016-03-02	株式会社大熊	稳定的人生长激素液体制剂
US7923425B2 (en) *	2006-08-21	2011-04-12	Henkel Ag & Co. Kgaa	Low-foaming, acidic low-temperature cleaner and process for cleaning surfaces
US7833527B2 (en)	2006-10-02	2010-11-16	Amgen Inc.	Methods of treating psoriasis using IL-17 Receptor A antibodies
US7951368B2 (en) *	2007-06-25	2011-05-31	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
EP2173163A4 (en) *	2007-07-06	2010-12-08	Glaxosmithkline Llc	ANTIBODY FORMULATIONS
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
AU2009203809B2 (en)	2008-01-09	2013-07-25	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
CA3083198A1 (en)	2008-03-26	2009-10-01	Oramed Ltd.	Methods and compositions for oral administration of proteins
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
TW201032826A (en) *	2008-11-17	2010-09-16	Genentech Inc	Method and formulation for reducing aggregation of a macromolecule under physiological conditions
BRPI1006519A2 (pt) *	2009-03-06	2016-08-09	Genentech Inc	formulação de anticorpos
KR101853606B1 (ko) *	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
NZ623910A (en)	2009-07-28	2016-06-24	Shire Human Genetic Therapies	Compositions and methods for treating gaucher disease
EP2458990B1 (en) *	2009-07-28	2016-03-30	Merck Sharp & Dohme Corp.	Methods for producing high concentration lyophilized pharmaceutical formulations
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
EP2501367B1 (en) *	2009-11-17	2015-01-21	Ipsen Pharma S.A.S.	Formulation for HGH and RHIGF-1 combination
SI3295957T1 (sl)	2010-01-15	2020-02-28	Kirin-Amgen, Inc.	Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
EP3409289B1 (en)	2010-02-26	2020-09-30	Novo Nordisk A/S	Stable antibody containing compositions
RS59830B1 (sr)	2010-03-01	2020-02-28	Bayer Healthcare Llc	Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
RU2012153786A (ru)	2010-05-28	2014-07-10	Ново Нордиск А/С	Стабильные многодозовые композиции, содержащие антитело и консервант
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
WO2012036746A1 (en)	2010-09-15	2012-03-22	Randall J Mrsny	Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en)	2010-09-15	2022-02-15	Applied Molecular Transport Inc.	Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013001044A1 (en)	2011-06-28	2013-01-03	Leukocare Ag	Method for preventing the unfolding of a (poly) peptide and/or inducing the (re- ) folding of a (poly) peptide
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013063510A1 (en)	2011-10-28	2013-05-02	Integritybio Inc.	Protein formulations containing amino acids
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US8613919B1 (en)	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
JP6171331B2 (ja) *	2012-12-25	2017-08-02	東ソー株式会社	Ｆｃ結合性タンパク質の精製方法および定量方法
EP2941267B1 (en)	2013-01-03	2022-11-16	Oramed Ltd.	Compositions for use in treating nafld
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
AR095398A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida
AR095399A1 (es)	2013-03-13	2015-10-14	Genentech Inc	Formulaciones con oxidación reducida, método
SI2968467T1 (sl) *	2013-03-13	2020-11-30	F. Hoffmann-La Roche Ag	Pripravki z zmanjšano oksidacijo
AR095348A1 (es)	2013-03-15	2015-10-07	Genentech Inc	Medios de cultivo celular y métodos de producción de anticuerpos
IL312865B2 (en)	2013-09-11	2025-06-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-lowering agents
JP2014062100A (ja) *	2013-11-05	2014-04-10	Glaxosmithkline Llc	抗体処方
CN112957455A (zh)	2014-01-09	2021-06-15	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
EP3091965A1 (en)	2014-01-09	2016-11-16	Sanofi	Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604706TA (en)	2014-01-09	2016-07-28	Sanofi Sa	Stabilized pharmaceutical formulations of insulin aspart
US10260111B1 (en)	2014-01-20	2019-04-16	Brett Eric Etchebarne	Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
SG11201610183XA (en)	2014-05-07	2017-01-27	Applied Molecular Transp Llc	Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US20160074515A1 (en)	2014-06-20	2016-03-17	Reform Biologics, Llc	Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en)	2014-06-20	2022-06-14	Comera Life Sciences, Inc.	Excipient compounds for protein processing
US10478498B2 (en)	2014-06-20	2019-11-19	Reform Biologics, Llc	Excipient compounds for biopolymer formulations
SG11201702614SA (en)	2014-10-01	2017-04-27	Eagle Biolog Inc	Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
AR103173A1 (es) *	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6247241B2 (ja) *	2015-02-27	2017-12-13	ノバルティスアーゲー	抗体処方
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10576129B2 (en) *	2015-04-21	2020-03-03	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Nerve growth factor composition and powder injection
EP3397287B8 (en)	2015-12-30	2025-07-23	F. Hoffmann-La Roche AG	Formulations with reduced degradation of polysorbate
WO2018038301A1 (en) *	2016-08-26	2018-03-01	Hugel Inc.	Stabilized liquid formulation of botulinum toxin and preparation method thereof
ES3064802T3 (en)	2016-10-21	2026-04-29	Amgen Inc	Pharmaceutical formulations and methods of making the same
JP7165717B2 (ja)	2017-03-15	2022-11-04	パンディオン・オペレーションズ・インコーポレイテッド	標的免疫寛容
AU2018273914A1 (en)	2017-05-24	2019-11-14	Pandion Operations, Inc.	Targeted immunotolerance
US20210137809A1 (en) *	2017-06-14	2021-05-13	Biosolution Co., Ltd	Cosmetic composition for wrinkle reduction or anti-inflammation, containing substance p
US12396943B2 (en) *	2017-08-08	2025-08-26	Csl Behring Ag	Hemopexin formulations
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
USRE50550E1 (en)	2017-12-06	2025-08-26	Pandion Operations, Inc.	IL-2 muteins and uses thereof
KR20250174998A (ko)	2018-03-08	2025-12-15	어플라이드 몰레큘라 트랜스포트 인크.	경구 전달용 독소-유래 전달 구조체
CA3093386A1 (en)	2018-03-08	2019-09-12	Applied Molecular Transport Inc.	Toxin-derived delivery constructs for oral delivery
SG11202012299SA (en) *	2018-06-13	2021-01-28	Akron Biotechnology Llc	Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
CA3141327A1 (en)	2019-05-20	2020-11-26	Pandion Operations, Inc.	Madcam targeted immunotolerance
CN114599665A (zh)	2019-08-16	2022-06-07	应用分子转运公司	组合物、制剂及白细胞介素产生和纯化
CA3167217A1 (en)	2020-01-13	2021-07-22	Durect Corporation	Sustained release drug delivery systems with reduced impurities and related methods
KR20220140500A (ko) *	2020-01-13	2022-10-18	압테보 리서치 앤드 디벨롭먼트 엘엘씨	약물 전달 시스템 성분에 대한 치료제 단백질의 흡착을 방지하기 위한 방법 및 조성물
WO2021168079A1 (en)	2020-02-21	2021-08-26	Pandion Operations, Inc.	Tissue targeted immunotolerance with a cd39 effector
IL295826B2 (en) *	2020-03-31	2025-11-01	Hanmi Pharmaceutical Co Ltd	Novel immunostimulating il-2 analogs
CN116940358A (zh)	2021-01-12	2023-10-24	度勒科特公司	持续释放药物递送系统和有关的方法
WO2022192601A1 (en) *	2021-03-11	2022-09-15	89Bio, Inc.	Liquid formulations comprising mutant fgf-21 peptide pegylated conjugates
CN117120070B (zh) *	2021-03-11	2024-11-15	89生物公司	包含突变型fgf-21肽peg化缀合物的液体制剂
EP4609881A1 (en)	2022-10-26	2025-09-03	Nihon Medi-Physics Co., Ltd.	Radioactive pharmaceutical composition
EP4676515A1 (en) *	2023-03-09	2026-01-14	Merck Sharp & Dohme LLC	Formulations comprising actriia polypeptide variants
CN119405595A (zh) *	2024-03-14	2025-02-11	程度胜	含重组人白细胞介素-2的药物组合物、药物制剂及其制备方法
CN118593451B (zh) *	2024-08-08	2024-10-15	卡瑞济(北京)生命科技有限公司	一种包含l-精氨酸的抗肿瘤药物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4966843A (en)	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
JPS60215631A (ja) *	1984-04-09	1985-10-29	Takeda Chem Ind Ltd	インタ−ロイキン−２組成物
EP0158487B1 (en)	1984-04-09	1991-08-28	Takeda Chemical Industries, Ltd.	Stable composition of interleukin-2
US4650674A (en) *	1984-07-05	1987-03-17	Genentech, Inc.	Synergistic cytotoxic composition
US5034225A (en) *	1985-12-17	1991-07-23	Genentech Inc.	Stabilized human tissue plasminogen activator compositions
JPH0645551B2 (ja) *	1986-01-07	1994-06-15	塩野義製薬株式会社	インタ−ロイキン−２組成物
US4894226A (en)	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4931543A (en)	1987-05-11	1990-06-05	Cetus Corporation	Process for recovering microbially produced interleukin-2
ATE82506T1 (de)	1987-08-21	1992-12-15	Imcera Group Inc	Stabilisierung von wachstumshormonen.
US4883661A (en)	1987-10-09	1989-11-28	Daly John M	Use of arginine as an lymphokine synergist
US5078997A (en) *	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
DE4111393A1 (de)	1991-04-09	1992-10-15	Behringwerke Ag	Stabilisierte faktor viii-praeparationen
FR2684878B1 (fr)	1991-12-12	1994-02-11	Roussel Uclaf	Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
IL107887A (en) *	1992-12-08	2003-07-06	Ambi Inc	Stabilized lanthionine containing bacteriocin compositions
US5358708A (en)	1993-01-29	1994-10-25	Schering Corporation	Stabilization of protein formulations
US5580856A (en) *	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
JP2000510813A (ja)	1995-02-06	2000-08-22	ジェネテイックス・インスティテュート・インコーポレイテッド	Ｉｌ−１２用処方
US5888968A (en) *	1995-06-07	1999-03-30	Chiron Corporation	TFPI formulation
EP0837883B1 (en)	1995-06-07	2005-08-10	Chiron Corporation	Method of solubilizing, purifying, and refolding protein
CA2226575C (en) *	1995-07-27	2011-10-18	Genentech, Inc.	Stabile isotonic lyophilized protein formulation
JP2001501619A (ja) *	1996-10-04	2001-02-06	アムジェンインコーポレーテッド	ｍｐｌリガンドを含有する医薬組成物
WO1998033920A2 (en) *	1997-01-31	1998-08-06	Human Genome Sciences, Inc.	Tissue factor pathway inhibitor-3
ATE367828T1 (de)	1998-04-03	2007-08-15	Novartis Vaccines & Diagnostic	Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
CN1245216C (zh) *	1999-10-04	2006-03-15	希龙公司	稳定化的含多肽的液体药物组合物
EP1282438B1 (en)	2000-05-10	2005-08-03	Novo Nordisk Health Care AG	Use of pharmaceutical composition comprising a factor viia and a factor xiii
JP4340062B2 (ja)	2000-10-12	2009-10-07	ジェネンテック・インコーポレーテッド	粘度の減少した濃縮タンパク質製剤
IL156488A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions

2000
- 2000-10-03 CN CNB008163286A patent/CN1245216C/zh not_active Expired - Fee Related
- 2000-10-03 PL PL00354987A patent/PL354987A1/xx not_active Application Discontinuation
- 2000-10-03 CZ CZ2004-1041A patent/CZ305123B6/cs not_active IP Right Cessation
- 2000-10-03 WO PCT/US2000/027156 patent/WO2001024814A1/en not_active Ceased
- 2000-10-03 PL PL370852A patent/PL211886B1/pl not_active IP Right Cessation
- 2000-10-03 AU AU78475/00A patent/AU783306B2/en not_active Ceased
- 2000-10-03 BR BR0014486-0A patent/BR0014486A/pt not_active Application Discontinuation
- 2000-10-03 HU HU0401975A patent/HU227347B1/hu unknown
- 2000-10-03 AT AT00968584T patent/ATE345810T1/de not_active IP Right Cessation
- 2000-10-03 DE DE60031999T patent/DE60031999T2/de not_active Expired - Lifetime
- 2000-10-03 HU HU0800692A patent/HU0800692D0/hu unknown
- 2000-10-03 IL IL14900800A patent/IL149008A0/xx unknown
- 2000-10-03 JP JP2001527813A patent/JP2003510368A/ja active Pending
- 2000-10-03 AT AT04021066T patent/ATE464062T1/de not_active IP Right Cessation
- 2000-10-03 DE DE60044213T patent/DE60044213D1/de not_active Expired - Lifetime
- 2000-10-03 CA CA002386228A patent/CA2386228A1/en not_active Abandoned
- 2000-10-03 PT PT04021066T patent/PT1491208E/pt unknown
- 2000-10-03 NZ NZ529856A patent/NZ529856A/en unknown
- 2000-10-03 CA CA2477857A patent/CA2477857C/en not_active Expired - Lifetime
- 2000-10-03 NZ NZ535205A patent/NZ535205A/en not_active IP Right Cessation
- 2000-10-03 CN CNB2004100858470A patent/CN100389821C/zh not_active Expired - Lifetime
- 2000-10-03 CZ CZ20021186A patent/CZ20021186A3/cs unknown
- 2000-10-03 EP EP00968584A patent/EP1220682B1/en not_active Expired - Lifetime
- 2000-10-03 EP EP04021066A patent/EP1491208B1/en not_active Expired - Lifetime
- 2000-10-03 HU HU0203133A patent/HUP0203133A3/hu unknown
- 2000-10-03 ES ES00968584T patent/ES2276698T3/es not_active Expired - Lifetime
- 2000-10-03 BR BRPI0017437A patent/BRPI0017437B8/pt not_active IP Right Cessation
- 2000-10-03 US US09/677,643 patent/US6525102B1/en not_active Expired - Fee Related
2002
- 2002-04-03 NO NO20021567A patent/NO20021567L/no not_active Application Discontinuation
- 2002-04-04 IL IL149008A patent/IL149008A/en active IP Right Grant
- 2002-11-18 US US10/299,039 patent/US7030086B2/en not_active Expired - Fee Related
2004
- 2004-10-15 NO NO20044406A patent/NO20044406L/no not_active Application Discontinuation
- 2004-10-29 JP JP2004317319A patent/JP2005068158A/ja active Pending
2005
- 2005-12-05 US US11/293,379 patent/US20060093598A1/en not_active Abandoned
- 2005-12-05 US US11/293,322 patent/US7807142B2/en not_active Expired - Fee Related
2006
- 2006-01-13 AU AU2006200141A patent/AU2006200141B2/en not_active Ceased
2007
- 2007-12-18 IL IL188230A patent/IL188230A0/en unknown

Also Published As

Publication number	Publication date
ES2276698T3 (es)	2007-07-01
US20060093598A1 (en)	2006-05-04
AU2006200141B2 (en)	2009-07-02
HU0800692D0 (en)	2009-01-28
HUP0203133A3 (en)	2005-07-28
JP2005068158A (ja)	2005-03-17
DE60031999D1 (de)	2007-01-04
PL211886B1 (pl)	2012-07-31
CZ305123B6 (cs)	2015-05-13
IL149008A (en)	2009-11-18
BRPI0017437B1 (pt)	2016-06-07
NO20021567D0 (no)	2002-04-03
HU0401975D0 (en)	2004-11-29
AU783306B2 (en)	2005-10-13
NZ535205A (en)	2006-01-27
CN1245216C (zh)	2006-03-15
AU2006200141A1 (en)	2006-02-09
CN1636592A (zh)	2005-07-13
PL354987A1 (en)	2004-03-22
JP2003510368A (ja)	2003-03-18
HUP0203133A2 (hu)	2002-12-28
US6525102B1 (en)	2003-02-25
US7807142B2 (en)	2010-10-05
US20060093576A1 (en)	2006-05-04
CA2477857A1 (en)	2001-04-12
NO20021567L (no)	2002-05-22
EP1491208A1 (en)	2004-12-29
DE60031999T2 (de)	2007-06-06
NO20044406L (no)	2002-05-22
WO2001024814A1 (en)	2001-04-12
ATE464062T1 (de)	2010-04-15
CZ20021186A3 (cs)	2002-11-13
CN100389821C (zh)	2008-05-28
IL149008A0 (en)	2002-11-10
NZ529856A (en)	2005-09-30
CN1402640A (zh)	2003-03-12
AU7847500A (en)	2001-05-10
EP1220682B1 (en)	2006-11-22
US7030086B2 (en)	2006-04-18
BRPI0017437B8 (pt)	2021-05-25
ATE345810T1 (de)	2006-12-15
US20030180253A1 (en)	2003-09-25
CA2477857C (en)	2012-04-10
DE60044213D1 (de)	2010-05-27
IL188230A0 (en)	2008-03-20
HUP0401975A3 (en)	2010-01-28
EP1491208B1 (en)	2010-04-14
EP1220682A1 (en)	2002-07-10
HU227347B1 (en)	2011-04-28
CA2386228A1 (en)	2001-04-12
PT1491208E (pt)	2010-05-12
BR0014486A (pt)	2002-09-17

Legal Events

Date	Code	Title	Description
2009-05-26	B25D	Requested change of name of applicant approved	Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) Free format text: ALTERADO DE: CHIRON CORPORATION
2010-10-19	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2011-06-21	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2012-01-31	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2013-01-22	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2014-08-19	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2016-05-24	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2016-06-07	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/06/2016, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/10/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-06-01	B21A	Patent or certificate of addition expired [chapter 21.1 patent gazette]	Free format text: PATENTE EXTINTA EM 03/10/2020

Publication	Publication Date	Title
NO20021567L (no)	2002-05-22	Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger
EP1401473A4 (en)	2004-07-28	TRANSPORTER WITH SPACED ARGININE PARTICLES
UY27320A1 (es)	2003-02-28	Nuevas composiciones farmacéuticas
TR200200252T2 (tr)	2002-05-21	Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı
BG106439A (en)	2002-11-29	Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
CA2411754A1 (en)	2002-01-10	4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
BR9506452A (pt)	1997-09-02	Composto heterocíclico processo de preparação do composto heterocíclico composição farmacêutica composição farmacêutica adequada para o tratamento de inflamação neurogênica processo de tratamento de inflamação neurogênica em um individuo necessitado de tal tratamento e uso de um composto heterocíclico
NO20051102L (no)	2005-05-04	Sulfonylamino-eddiksyre-derivater
WO1997007794A1 (en)	1997-03-06	Composition for local anesthesia
ES2184310T3 (es)	2003-04-01	Formulacion autoemulsionante para compuestos lipofilos acidos.
ATE404176T1 (de)	2008-08-15	Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
CA2480226A1 (en)	2003-10-02	Stable pharmaceutical composition containing factor viii
DK1588707T3 (da)	2009-03-09	Stabilt fast medicinsk præparat til oral administration af ramosetron
EA200401298A1 (ru)	2005-02-24	Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение
BR0211060A (pt)	2004-07-20	Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano
FR2846883B1 (fr)	2004-12-24	Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
IL168836A (en)	2010-12-30	Pyrimidine-sulfamides and their use as endothelin receptor antagonist
BR9908479A (pt)	2000-12-05	Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio
DE69918098D1 (de)	2004-07-22	Neue suesstoffzusammensetzungen
ATE335409T1 (de)	2006-09-15	Suesstoffzusammensetzung
DE3687945D1 (de)	1993-04-15	((((3-pyridinyl)methylen)amino)oxy)alkansaeuren und -ester.
DE69208171D1 (de)	1996-03-21	Gallensäuren enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
JPH04270227A (ja)	1992-09-25	ヒト組織プラスミノーゲン活性化因子含有組成物
DK0817643T3 (da)	2007-07-30	Forbindelser og præparater til administration af aktive midler
ES8104271A1 (es)	1981-04-16	Procedimiento para la preparacion de 5-(2-((3-(1,3-benzodio-sol-5-il)-1-metilpropil)amino)-1-hidroxietil-2-metoxibenza- mida y de sus sales e isomeros opticos farmaceuticamente aceptables